Marks Group Wealth Management Inc Purchases 305 Shares of Thermo Fisher Scientific Inc. $TMO

Marks Group Wealth Management Inc raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 9,692 shares of the medical research company’s stock after acquiring an additional 305 shares during the period. Marks Group Wealth Management Inc’s holdings in Thermo Fisher Scientific were worth $3,930,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of TMO. Brighton Jones LLC raised its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Vest Financial LLC raised its stake in shares of Thermo Fisher Scientific by 73.4% during the 1st quarter. Vest Financial LLC now owns 3,188 shares of the medical research company’s stock worth $1,586,000 after purchasing an additional 1,349 shares in the last quarter. Impact Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 7.3% during the 1st quarter. Impact Capital Partners LLC now owns 1,024 shares of the medical research company’s stock worth $510,000 after purchasing an additional 70 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 21.6% during the 1st quarter. Sivia Capital Partners LLC now owns 891 shares of the medical research company’s stock worth $443,000 after purchasing an additional 158 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $543.88 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock’s fifty day moving average price is $482.58 and its two-hundred day moving average price is $446.77. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The firm has a market cap of $205.38 billion, a price-to-earnings ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the firm posted $5.37 EPS. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Raymond James Financial reissued an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays boosted their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a report on Thursday. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.